A large trial by Pfizer has found that its COVID-19 oral antiviral treatment Paxlovid was not effective at preventing coronavirus infection in people living with someone infected with the virus, said the disappointed drugmaker.
The trial enrolled 3 000 adults who were household contacts exposed to an individual who was experiencing symptoms and had recently tested positive for COVID-19. They were either given Paxlovid for five or 10 days or a placebo.
Reuters reports that those who took the five-day course were found to be 32% less likely to become infected than the placebo group. That rose to 37% with 10 days of Paxlovid. However, the results were not statistically significant and thus possibly due to chance.
Pfizer said safety data in the trial were consistent with previous studies, which had shown the pills to be nearly 90% effective at preventing hospitalisation or death in COVID patients at high risk of severe illness when taken for five days shortly after symptom onset.
“While we are disappointed in the outcome of this particular study, these results do not affect the strong efficacy and safety data we’ve observed in our earlier trial for the treatment of COVID-19 patients," Pfizer chief executive Albert Bourla said.
Pfizer said Paxlovid, which consists of two different antiviral drugs, is currently approved or authorised for conditional or emergency use in more than 60 countries across the globe to treat high-risk COVID-19 patients.
See more from MedicalBrief archives:
Paxlovid as a treatment for long COVID
Pfizer’s anti-COVID oral tablets show robust efficacy
Pfizer to deliver generic version of its COVID pill to 95 countries